CN102940658A - Medicine composition for treating cardia-cerebrovascular diseases - Google Patents
Medicine composition for treating cardia-cerebrovascular diseases Download PDFInfo
- Publication number
- CN102940658A CN102940658A CN2012104293977A CN201210429397A CN102940658A CN 102940658 A CN102940658 A CN 102940658A CN 2012104293977 A CN2012104293977 A CN 2012104293977A CN 201210429397 A CN201210429397 A CN 201210429397A CN 102940658 A CN102940658 A CN 102940658A
- Authority
- CN
- China
- Prior art keywords
- fructus choerospondiatis
- caulis sargentodoxae
- pharmaceutical composition
- herba erigerontis
- cardiovascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a medicine composition for treating cardia-cerebrovascular diseases, comprising fructus choerospondiatis, sargentodoxa cuneata and herba erigerontis. The medicine composition disclosed herein can benefit qi and blood circulation, disperse blood stasis and dredge collateral, tranquilize mind and nourish heart, and especially has good curative effect on cerebrovascular diseases.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of cardiovascular and cerebrovascular disease, relating in particular to a kind of is the medicament that raw material is made by Fructus Choerospondiatis, Caulis Sargentodoxae and Herba Erigerontis.
Background technology
People's health in the cardiovascular and cerebrovascular disease serious threats such as cerebral thrombosis, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia, heart failure, arrhythmia, learn according to Epidemiological study, the M ﹠ M of cardiovascular and cerebrovascular disease is all in rising trend in recent years, the sickness rate of cardiovascular and cerebrovascular disease is 140-200/10 ten thousand people in the worldwide, its average mortality is 1,00/,100,000 people, has leapt to first of the various diseases at the mortality rate of China's cardiovascular and cerebrovascular disease.In the pathogenic factor of cardiovascular and cerebrovascular disease, atherosclerosis is main cause, and it is the pathogenesis basis of hypertension, coronary heart disease, myocardial infarction, apoplexy cardiovascular and cerebrovascular disease.Suppressing the blood coagulation, improve blood fluidity, is one of key areas of cardiovascular medicament research and development.
In the medicine of cardiovascular and cerebrovascular disease, Chinese medicine and western medicine is all used, and Chinese medicine is little and occupy the larger market share with its toxic and side effects, but its curative effect not rapidly, effective ingredient is not obvious, medication dose is large.
Summary of the invention
Purpose of the present invention just provides a kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, and this pharmaceutical composition can be regulated the flow of vital energy, the effect of promoting blood circulation to remove obstruction in the collateral.
The technical solution adopted for the present invention to solve the technical problems is:
A kind of pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease, it is to be the medicament that raw material is made by Fructus Choerospondiatis, Caulis Sargentodoxae and Herba Erigerontis.
The weight proportion of the used medicine material of pharmaceutical composition of the present invention can be Fructus Choerospondiatis 5-15 part, Caulis Sargentodoxae 3-12 part, Herba Erigerontis 1-6 part.
The optimum ratio of the used medicine material of pharmaceutical composition of the present invention is: Fructus Choerospondiatis 7-12 part, Caulis Sargentodoxae 4-8 part, Herba Erigerontis 2-4 part.
The raw materials used best proportioning of pharmaceutical composition of the present invention is: 9 parts of Fructus Choerospondiatis, 6 parts of Caulis Sargentodoxae, 3 parts of Herba Erigerontiss.
The dosage form of pharmaceutical composition of the present invention can be any existing pharmaceutical dosage form in injection, transfusion, powder pin, drop pill, tablet, slow releasing tablet, capsule, soft capsule, the granule.
Pharmaceutical composition of the present invention can be applicable to the treatment of the cardiovascular and cerebrovascular disease such as cerebral thrombosis, cerebral ischemia, coronary heart diseases and angina pectoris, myocardial ischemia, heart failure, arrhythmia.
Pharmaceutical composition of the present invention can adopt but be not limited to following methods:
(1) get the Fructus Choerospondiatis medical material by formula proportion, with the 50-95% alcohol reflux of 8-10 times of volume 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, drying gets Fructus Choerospondiatis extract.
(2) get the Caulis Sargentodoxae medical material by formula proportion, the 70-95% ethanol that adds 8-10 times of volume is heated to 60-80 ℃ and extracts three times, and each 0.5-1h collects merge extractive liquid,, and stirring is also centrifugal, gets supernatant concentration, drying, gets Caulis Sargentodoxae extract.
(3) get the Herba Erigerontis medical material by formula proportion and add 8-10 times of water, decoct 3 times, each 0.5-1h, decoction liquor adds ethanol, and to make pure content be 55%, stir, place, filter, decompression filtrate recycling ethanol is to relative density 1.10(50 ℃), regulate pH value to 2 with hydrochloric acid, in 55 ℃ of insulation 6-8h, filter, vacuum drying gets Herba Erigerontis extract.
(4) the said extracted thing is mixed, make acceptable various pharmaceutical dosage form.
In the pharmaceutical composition of the present invention, five fruits of Fructus Choerospondiatis another name, Fructus Choerospondiatis, Fructus Dracontomeli Duperreani, Fructus Choerospondiatis, sweet in the mouth, acid, property is flat.The function of have promoting flow of QI and blood, nourish heart, calming the nerves.Be used for qi depression to blood stasis, the thoracic obstruction is had a pain, shortness of breath and palpitation, irritability.Modern pharmacological research shows, Fructus Choerospondiatis has antiarrhythmic effect, and the rabbit platelet aggregation that ADP is induced has obvious inhibitory action, has aobvious effect after administration in 10 minutes, peaks in 30 minutes, continues to act on after 2 hours to weaken gradually.
The Caulis Sargentodoxae nature and flavor are flat, bitter; Return large intestine, Liver Channel, have heat-clearing and toxic substances removing, invigorate blood circulation, the function of dispeling the wind.Be used for abdominalgia with intestinal abscess, amenorrhea dysmenorrhea, rheumatic arthralgia, tumbling and swelling.
Herba Erigerontis sweet in the mouth, warm in nature; Has expelling cold and relieving exterior syndrome, relaxing muscles and tendons to promote blood circulation, pain relieving, the function of removing food stagnancy.Take Herba Erigerontis as main, in conjunction with other integrative medicine therapy, there is certain curative effect in the rear something lost such as treatment hypertensive cerebral hemorrhage, cerebral thrombosis, cerebral embolism, polyneuritis, chronic arachnoiditis paralysed disease.
Compared with prior art, the invention has the beneficial effects as follows: this pharmaceutical composition is the medicament that raw material is made by Fructus Choerospondiatis, Caulis Sargentodoxae and Herba Erigerontis, can relaxing muscles and tendons to promote blood circulation, blood-activating analgetic, again can tranquilizing by nourishing the heart, and QI and blood is ruled together, and curative effect is significantly improved.Prove that through pharmacodynamics test it is evident in efficacy.
The specific embodiment
The present invention is described in further detail below in conjunction with the specific embodiment.
Embodiment 1
The pharmaceutical composition of the treatment cardiovascular and cerebrovascular disease that the present embodiment is enumerated is comprised of the medicinal raw material of following weight: Fructus Choerospondiatis 9g, Caulis Sargentodoxae 6g, Herba Erigerontis 3g.
Above-mentioned medicinal raw material is prepared into soft capsule, and preparation method is as follows:
(1) get the Fructus Choerospondiatis medical material by formula proportion, with 95% alcohol reflux of 8 times of volumes 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, drying gets Fructus Choerospondiatis extract.
(2) get the Caulis Sargentodoxae medical material by formula proportion, 95% ethanol that adds 10 times of volumes is heated to 60-80 ℃ and extracts three times, and each 0.5h collects merge extractive liquid,, and stirring is also centrifugal, gets supernatant concentration, drying, gets Caulis Sargentodoxae extract.
(3) get the Herba Erigerontis medical material by formula proportion and add 8 times of water, decoct 3 times, each 0.5h, decoction liquor adds ethanol, and to make pure content be 55%, stir, place, filter, decompression filtrate recycling ethanol is to relative density 1.10(50 ℃), regulate pH value to 2 with hydrochloric acid, in 55 ℃ of insulation 6h, filter, vacuum drying gets Herba Erigerontis extract.
(4) with said mixture and vegetable oil 25g, mixing is made capsule casing material with gelatin, is pressed into soft capsule.
Embodiment 2
The pharmaceutical composition of the treatment cardiovascular and cerebrovascular disease that the present embodiment is enumerated is comprised of the medicinal raw material of following weight: Fructus Choerospondiatis 5g, Caulis Sargentodoxae 3g, Herba Erigerontis 1g.
Above-mentioned medicinal raw material is prepared into injectable powder, and preparation method is as follows:
(1) get the Fructus Choerospondiatis medical material by formula proportion, with 50% alcohol reflux of 10 times of volumes 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, drying gets Fructus Choerospondiatis extract.
(2) get the Caulis Sargentodoxae medical material by formula proportion, 70% ethanol that adds 10 times of volumes is heated to 60-80 ℃ and extracts three times, and each 1h collects merge extractive liquid,, and stirring is also centrifugal, gets supernatant concentration, drying, gets Caulis Sargentodoxae extract.
(3) get the Herba Erigerontis medical material by formula proportion and add 10 times of water, decoct 3 times, each 1h, decoction liquor adds ethanol, and to make pure content be 55%, stir, place, filter, decompression filtrate recycling ethanol is to relative density 1.10(50 ℃), regulate pH value to 2 with hydrochloric acid, in 55 ℃ of insulation 8h, filter, vacuum drying gets Herba Erigerontis extract.
(4) said mixture is dissolved in the 1000mL water for injection, filters, adopt existing preparation of injection, make injectable powder.
Embodiment 3
The pharmaceutical composition of the treatment cardiovascular and cerebrovascular disease that the present embodiment is enumerated is comprised of the medicinal raw material of following weight: Fructus Choerospondiatis 15g, Caulis Sargentodoxae 12g, Herba Erigerontis 6g.
Above-mentioned medicinal raw material is prepared into capsule, and preparation method is as follows:
(1) get the Fructus Choerospondiatis medical material by formula proportion, with 95% alcohol reflux of 8 times of volumes 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, drying gets Fructus Choerospondiatis extract.
(2) get the Caulis Sargentodoxae medical material by formula proportion, 95% ethanol that adds 8 times of volumes is heated to 60-80 ℃ and extracts three times, and each 0.5h collects merge extractive liquid,, and stirring is also centrifugal, gets supernatant concentration, drying, gets Caulis Sargentodoxae extract.
(3) get the Herba Erigerontis medical material by formula proportion and add 8 times of water, decoct 3 times, each 0.5h, decoction liquor adds ethanol, and to make pure content be 55%, stir, place, filter, decompression filtrate recycling ethanol is to relative density 1.10(50 ℃), regulate pH value to 2 with hydrochloric acid, in 55 ℃ of insulation 6h, filter, vacuum drying gets Herba Erigerontis extract.
(4) with said mixture and starch 100g mix homogeneously, adopt capsules preparation technique, make capsule.
Test example
The curative effect of medicine of the present invention and advantage thereof are proved by following pharmacodynamics test:
The test one: on senile rat in the thrombotic impact of body
Principle: use unidirectional current continued stimulus common carotid artery 7 minutes, cause the tunica intima damage, activate platelet and blood coagulation system, vascular endothelial cell injury makes PGI simultaneously
2Synthetic and discharge and reduce, cause and form gradually mixed thrombus in the carotid artery vascular.When carotid artery vascular endogenous cause of ill thrombosis and during plug flow, blood vessel far-end temperature bust then.With temperature sensor monitors blood vessel surface variations in temperature, by the instrument automatic alarm, record begins to temperature bust required time from stimulation, claims duration of congestion OT, i.e. thrombus formation time.Time is shorter, and expression more easily forms thrombosis; Otherwise the time is longer, represents more difficult formation thrombosis.
But senile rat self-assembling formation blood stasis body constitution easily forms thrombus in vivo.Young rat then is difficult for forming thrombosis.Therefore the test in the positive contrast of senile rat, with the negative contrast of young rat.
Material: male rat.Young group Mus 3-4 in the age month is about body weight 250g.Old group Mus 24-27 in the age month is about body weight 500g.Equipment: rat operation platform, operating scissors, ophthalmic tweezers, mosquito forceps, mosquito clamp, rat oral gavage syringe needle, instrument for detecting internal thrombosis.
Medicine and reagent:
9 parts of test example 1:(Fructus Choerospondiatis, 6 parts of Caulis Sargentodoxae, 3 parts of Herba Erigerontiss);
5 parts of test example 2:(Fructus Choerospondiatis, 4 parts of Caulis Sargentodoxae, 2 parts of Herba Erigerontiss);
15 parts of test example 3:(Fructus Choerospondiatis, 12 parts of Caulis Sargentodoxae, 6 parts of Herba Erigerontiss);
9 parts of Comparative Examples 1:(Fructus Choerospondiatis, 6 parts of Caulis Sargentodoxae);
9 parts of Comparative Examples 2:(Fructus Choerospondiatis, 3 parts of Herba Erigerontiss).
Above medicine adopts following method to be prepared into test sample:
(1) get the Fructus Choerospondiatis medical material by formula proportion, with 95% alcohol reflux of 8 times of volumes 3 times, each 1.5h, extracting liquid filtering, merging filtrate, concentrating under reduced pressure, drying gets Fructus Choerospondiatis extract.
(2) get the Caulis Sargentodoxae medical material by formula proportion, 95% ethanol that adds 10 times of volumes is heated to 60-80 ℃ and extracts three times, and each 0.5h collects merge extractive liquid,, and stirring is also centrifugal, gets supernatant concentration, drying, gets Caulis Sargentodoxae extract.
(3) get the Herba Erigerontis medical material by formula proportion and add 8 times of water, decoct 3 times, each 0.5h, decoction liquor adds ethanol, and to make pure content be 55%, stir, place, filter, decompression filtrate recycling ethanol is to relative density 1.10(50 ℃), regulate pH value to 2 with hydrochloric acid, in 55 ℃ of insulation 6h, filter, vacuum drying gets Herba Erigerontis extract.
(4) the said extracted thing is mixed, namely get corresponding test sample.
Dosage is 1.42g/Kg; 20mg/mL pentobarbital sodium solution; Normal saline.
Method: experimental group is only given old group rat oral gavage 2mL/ every day, and positive controls senile rat and negative control group young rat gavage distilled water 2mL/, continuous 14 days.Drug withdrawal fasting on the same day.Lumbar injection 20mg/mL pentobarbital sodium 0.2mL/100g next day (body weight).Cut skin of neck, separate right carotid artery, transfer stimulating electrode at the carotid artery near-end, far-end is transferred the temperature gauge head that connects instrument.Open instrument switch, give 1.5mV galvanic stimulation 7 minutes with damage carotid artery endotheliocyte by stimulating electrode, along with carotid canal intracavity thrombosis forms gradually, blood flow is blocked gradually, and the temperature of carotid artery far-end descends gradually.When blood flow is blocked fully, the temperature bust, instrument is reported to the police, and shows duration of congestion OT, and the OT time is shorter, more easily forms thrombosis; The OT time is longer, more difficult formation thrombosis.
Experimental result is carried out statistical test.Concrete numerical value and the results are shown in Table one.
Table one: on senile rat in the thrombotic impact of body
By table one result of the test as can be known, senile rat OT is obviously short than young rat, illustrates easily to form thrombosis.But the administration group is significant prolongation OT all, and the application's effect of drugs is (P＜0.01) better.
Above result shows, the application's medicine is effective than control drug.
Claims (4)
1. pharmaceutical composition for the treatment of cardiovascular and cerebrovascular disease is characterized in that it is is the medicament that raw material is made by Fructus Choerospondiatis, Caulis Sargentodoxae and Herba Erigerontis.
2. treatment cardiovascular and cerebrovascular disease according to claim 1 pharmaceutical composition of the present invention, the weight that it is characterized in that used medicine material are joined and are Fructus Choerospondiatis 5-15 part, Caulis Sargentodoxae 3-12 part, Herba Erigerontis 1-6 part.
3. treatment cardiovascular and cerebrovascular disease according to claim 2 pharmaceutical composition of the present invention, the weight that it is characterized in that used medicine material are joined and are Fructus Choerospondiatis 7-12 part, Caulis Sargentodoxae 4-8 part, Herba Erigerontis 2-4 part.
4. treatment cardiovascular and cerebrovascular disease according to claim 3 pharmaceutical composition of the present invention, the weight that it is characterized in that used medicine material are joined and are 9 parts of Fructus Choerospondiatis, 6 parts of Caulis Sargentodoxae, 3 parts of Herba Erigerontiss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104293977A CN102940658A (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating cardia-cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012104293977A CN102940658A (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating cardia-cerebrovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102940658A true CN102940658A (en) | 2013-02-27 |
Family
ID=47723718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012104293977A Pending CN102940658A (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating cardia-cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102940658A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104367725A (en) * | 2014-11-10 | 2015-02-25 | 成都果睿医药科技有限公司 | Erigeron breviscapus-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
| CN104435106A (en) * | 2014-11-10 | 2015-03-25 | 成都果睿医药科技有限公司 | Medicine composition containing salviae miltiorrhizae for treating cardiovascular and cerebrovascular diseases |
| CN107029008A (en) * | 2017-06-16 | 2017-08-11 | 佳木斯大学附属第医院 | It is a kind of to treat medicine of heart failure and its preparation method and application |
-
2012
- 2012-10-31 CN CN2012104293977A patent/CN102940658A/en active Pending
Non-Patent Citations (5)
| Title |
|---|
| 李慧侠等: "灯盏细辛在心血管疾病和肾病治疗中的临床应用", 《华北煤炭医学院学报》 * |
| 毛水春等: "中药大血藤化学成分和药理活性的研究进展", 《天然产物研究与研发》 * |
| 申旭霁等: "广枣的化学成分", 《河南大学学报（医学版）》 * |
| 褚剑锋等: "灯盏细辛注射液在心血管内科中的应用新进展", 《福建中医学院学报》 * |
| 黎明: "关于广枣药学的学术性研究", 《北方药学》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104367725A (en) * | 2014-11-10 | 2015-02-25 | 成都果睿医药科技有限公司 | Erigeron breviscapus-containing pharmaceutical composition for treating cardiovascular and cerebrovascular diseases |
| CN104435106A (en) * | 2014-11-10 | 2015-03-25 | 成都果睿医药科技有限公司 | Medicine composition containing salviae miltiorrhizae for treating cardiovascular and cerebrovascular diseases |
| CN107029008A (en) * | 2017-06-16 | 2017-08-11 | 佳木斯大学附属第医院 | It is a kind of to treat medicine of heart failure and its preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN104107299A (en) | Traditional Chinese medicine mixture for treating dysmenorrhoea | |
| CN102357195B (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases, and preparation method and application thereof | |
| CN102940658A (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102961517B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN102940668B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102512470B (en) | Pharmaceutical composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application | |
| CN102940680B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN101152243B (en) | Traditional Chinese medicine for treating apoplexy and technique of preparing the same | |
| CN102641357B (en) | Medicament for treating hypertension and preparation method thereof | |
| CN102940669B (en) | A pharmaceutical composition for treating cardiovascular and cerebrovascular diseases | |
| CN104435213A (en) | Persimmon-leaf-containing traditional Chinese medicine composition for treating cardia-cerebrovascular disease | |
| CN101032534B (en) | Method of preparing Ilex rotunda Thunb total saponins and the application thereof | |
| CN102940675B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940657A (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN102940676B (en) | Medicine composition for treating cardia-cerebrovascular diseases | |
| CN104740283A (en) | Tranquilizing and intelligence-reinforcing capsule for treating insomnia and preparation method thereof | |
| CN104258034A (en) | Traditional Chinese medicine composition for boosting immunity | |
| CN104324134A (en) | Traditional Chinese medicine composition for improving microcirculation and preparation method of traditional Chinese medicine composition | |
| CN103463204A (en) | Medicine for treating constipation and preparation method thereof | |
| CN102406924B (en) | Medicine composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application thereof | |
| CN104398550A (en) | Ginkgo biloba containing Chinese medicinal composition for treatment of cardia-cerebrovascular diseases | |
| CN102940656B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN104352909A (en) | Traditional Chinese medicine composition containing Chinese angelica for treating cardiovascular and cerebtovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130227 |